TARGETED NANOTECHNOLOGY FOR ANTICANCER DRUG DELIVERY: CURRENT ISSUE AND CHALLENGE
The main aim of nonmaterials is optimization on site of action at tumors cells as well least toxicity by its formulation. Only to progress the biodistribution of neoplasia drugs, nanoparticles are designed for optimal size and surface individuality to expand their flow time within the blood circulation. They are also proficient to carry their laden active drugs to cancer cells by using the single functional changes of tumors, as like their improved permeability and preservation result and the tumor microenvironment. In this study report, we have discussed the current status of nanoparticles developed as targeting delivery systems for anticancer drugs.
Keywords: Cancer, Drug Delivery, Nanomedicine, Chemotherapy, Liposome
2. Wang X. et al. Application of nanotechnology in cancer therapy and imaging. CA Cancer J. Clin. 58, 97-110.
3. Vasir J.K. and Labhasetwar, V. (2007) Biodegradable nanoparticles for cytosolic delivery of therapeutics. Adv. Drug Deliv. Rev. 2008; 59:718-728.
4. Ferrari M. Cancer nanotechnology: opportunities and challenges. Nat. Rev. Cancer 2005; 5:161-171.
5. Sengupta S. et al. Temporal targeting of tumour cells and neovasculature with a nanoscale delivery system. Nature 2005; 436:568-572.
6. Bharali D.J. et al. Nanoparticles and cancer therapy: a concise review with emphasis on dendrimers. Int. J. Nanomed. 2009; 4:1-7.
7. Sparreboom A. et al. Comparative preclinical and clinical pharmacokinetics of a cremophor-free, nanoparticle albumin-bound paclitaxel (ABI-007) and paclitaxel formulated in Cremophor (Taxol). Clin. Cancer Res. 2005; 11:4136-4143.
8. Acharya S. et al. Targeted epidermal growth factor receptor nanoparticle bioconjugates for breast cancer therapy. Biomaterials 2009; 30:5737-5750.
9. Gabizon A. et al. Development of liposomal anthracyclines: from basics to clinical applications. J. Control. Release 1998; 53:275-279.
10. Sahoo S.K. and Labhasetwar, V. Nanotech approaches to drug delivery and imaging. Drug Discov. Today 2003; 8:1112-1120
11. Torchilin V. Antibody-modified liposomes for cancer chemotherapy. Expert Opin. Drug Deliv. 2008; 5:1003-1025.
12. Fassas A. and Anagnostopoulos, A. The use of liposomal daunorubicin (DaunoXome) in acute myeloid leukemia. Leuk. Lymphoma 2005; 46:795-802.
13. Charrois G.J. and Allen, T.M. Drug release rate influences the pharmacokinetics, biodistribution, therapeutic activity, and toxicity of pegylated liposomal doxorubicin formulations in murine breast cancer. Biochim. Biophys. Acta 2004; 1663:167-177.
14. Simoes, S. et al. On the formulation of pH-sensitive liposomes with long circulation times. Adv. Drug Deliv. Rev. 2004; 56:947-965.
15. Zhang Y. et al. Intravenous nonviral gene therapy causes normalization of striatal tyrosine hydroxylase and reversal of motor impairment in experimental Parkinsonism. Hum. Gene Ther. 2003; 14:1-12.
16. Leamon C.P. et al. Folate-liposome-mediated antisense oligodeoxynucleotide targeting to cancer cells: evaluation in vitro and in vivo. Bioconjug. Chem. 2003; 14:738-747.
17. Immordino M.L. et al. Stealth liposomes: reviewof the basic science, rationale, and clinical applications, existing and potential. Int. J. Nanomed. 2006; 1:297–315.
18. Misra R. and Sahoo, S.K. Intracellular trafficking of nuclear localization signal conjugated nanoparticles for cancer therapy. Eur. J. of Pharm. Sci. 2010; 39:152-163.
19. Kreuter J. et al. Direct evidence that polysorbate-80-coated poly(butylcyanoacrylate) nanoparticles deliver drugs to the CNS via specific mechanisms requiring prior binding of drug to the nanoparticles. Pharm. Res. 2003; 20:409-416.
20. Malam Y. et al. Liposomes and nanoparticles: nanosized vehicles for drug delivery in cancer. Trends Pharmacol. Sci. 2009; 30:592-599.
21. Owens D.E., 3rd and Peppas, N.A. Opsonization, biodistribution, and pharmacokinetics of polymeric nanoparticles. Int. J. Pharm. 2006; 307:93-102.
22. Rao K.S. et al. Targeting anti-HIV drugs to the CNS. Expert Opin. Drug Deliv. 2009; 6:771-784.
23. Mohanty C. and Sahoo S.K. The in vitro stability and in vivo pharmacokinetics of curcumin prepared as an aqueous nanoparticulate formulation. Biomaterials 2010; 31:6597-6611.
24. Vicent M.J. and Duncan R. Polymer conjugates: nanosized medicines for treating cancer. Trends Biotechnol. 2006; 24:39-47.
25. Portney N.G. and Ozkan M. Nano-oncology: drug delivery, imaging, and sensing. Anal. Bioanal. Chem. 2006; 384:620-630.
26. Rawat M. et al. Nanocarriers: promising vehicle for bioactive drugs. Biol. Pharm. Bull. 2006; 29:1790-1798.
27. Hamaguchi T. et al. NK105, a paclitaxel-incorporating micellar nanoparticle formulation, can extend in vivo antitumour activity and reduce the neurotoxicity of paclitaxel. Br. J. Cancer 2005; 92:1240-1246.
28. Lavasanifar A. et al. Poly (ethylene oxide)-block-poly (L-amino acid) micelles for drug delivery. Adv. Drug Deliv. Rev. 2002; 54:169-190.
29. Bae Y. et al. Preparation and biological characterization of polymeric micelle drug carriers with intracellular pH-triggered drug release property: tumor permeability, controlled subcellular drug distribution, and enhanced in vivo antitumor efficacy. Bioconjug. Chem. 2005; 16:122-130.
30. Nakanishi, T. et al. Development of the polymer micelle carrier system for doxorubicin. J. Control. Release 2001; 74:295–302
31. Torchilin V.P. et al. Immunomicelles: targeted pharmaceutical carriers for poorly soluble drugs. Proc. Natl. Acad. Sci. U. S. A. 2003; 100:6039-6044.
32. Mohanty C. et al. Curcumin-encapsulated MePEG/PCL diblock copolymeric micelles: a novel controlled delivery vehicle for cancer therapy. Nanomedicine (Lond.) 2010; 5:433-449.
33. Menjoge A.R. et al. Dendrimer-based drug and imaging conjugates: design considerations for nanomedical applications. Drug Discov. Today 2010; 15:171-185.
34. Svenson S. and Tomalia D.A. Dendrimers in biomedical applications– reflections on the field. Adv. Drug Deliv. Rev. 2005; 57:2106-2129.
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Authors who publish with this journal agree to the following terms:
- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution-NonCommercial 3.0 Unported License. that allows others to share the work with an acknowledgment of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgment of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).